Tiotropium bromide anhydrous
Spiriva, Stiolto (tiotropium bromide anhydrous) is an unknown pharmaceutical. Tiotropium bromide anhydrous was first approved as Spiriva on 2004-01-30.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Spiriva
CombinationsStiolto
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Olodaterol hydrochloride
+
Tiotropium bromide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| STIOLTO RESPIMAT | Boehringer Ingelheim | N-206756 RX | 2015-05-21 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| spiriva respimat | New Drug Application | 2023-05-23 |
| stiolto respimat | New Drug Application | 2022-01-24 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Olodaterol Hydrochloride / Tiotropium Bromide, Stiolto Respimat, Boehringer Ingelheim | |||
| 8733341 | 2030-10-16 | DP | |
| 7837235 | 2028-03-13 | DP | |
| 9027967 | 2027-03-31 | DP | |
| 7727984 | 2027-01-19 | DP | |
| 7396341 | 2026-10-10 | DP | |
| 7896264 | 2025-05-26 | DP | |
| 7220742 | 2025-05-12 | DS, DP | U-1703 |
| 8034809 | 2025-05-12 | U-1702 | |
| 7284474 | 2024-08-26 | DP | |
| 7056916 | 2023-12-07 | DS, DP | |
| 7491719 | 2023-11-10 | DS, DP | |
| 7786111 | 2023-11-10 | DP | |
| 8044046 | 2023-11-10 | U-1702 | |
| Tiotropium Bromide, Spiriva, Boehringer Ingelheim | |||
| 9010323 | 2030-04-19 | DP | |
| 7694676 | 2027-03-12 | DP | |
| 8022082 | 2026-01-19 | DP | U-1186 |
ATC Codes
R: Respiratory system drugs
— R03: Drugs for obstructive airway diseases
— R03A: Adrenergics, inhalants
— R03AL: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
— R03AL06: Olodaterol and tiotropium bromide
— R03AL10: Formoterol and tiotropium bromide
— R03B: Other drugs for obstructive airway diseases, inhalants in atc
— R03BB: Anticholinergics inhalants for obstructive airway diseases
— R03BB04: Tiotropium bromide
— R03BB54: Tiotropium bromide, combinations
HCPCS
No data
Clinical
Clinical Trials
351 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 13 | 43 | 104 | 84 | 39 | 279 |
| Asthma | D001249 | EFO_0000270 | J45 | 2 | 12 | 17 | 7 | 7 | 44 |
| Healthy volunteers/patients | — | 19 | — | — | 1 | 1 | 21 | ||
| Emphysema | D004646 | EFO_0000464 | J43 | — | — | — | 2 | 1 | 3 |
| Disease progression | D018450 | — | — | — | 1 | 1 | 2 | ||
| Chronic bronchitis | D029481 | J42 | 1 | — | — | 1 | — | 2 | |
| Bronchiectasis | D001987 | HP_0002110 | J47 | — | — | — | 1 | — | 1 |
| Respiratory sounds | D012135 | HP_0010307 | R06.1 | — | — | — | 1 | — | 1 |
| Airway obstruction | D000402 | — | — | — | 1 | — | 1 | ||
| Pulmonary emphysema | D011656 | J43 | — | — | — | 1 | — | 1 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 1 | 1 | 1 | — | — | 3 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | 1 | 2 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Spinal cord injuries | D013119 | EFO_1001919 | 1 | 1 | — | — | — | 2 | |
| Non-small-cell lung carcinoma | D002289 | — | 1 | — | — | — | 1 | ||
| Dyspnea | D004417 | HP_0002094 | R06.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
| Bronchial hyperreactivity | D016535 | — | — | — | — | 1 | 1 | ||
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 1 | 1 |
| Smoking | D012907 | EFO_0003768 | F17 | — | — | — | — | 1 | 1 |
| Airway remodeling | D056151 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tiotropium bromide anhydrous |
| INN | tiotropium bromide |
| Description | Tiotropium bromide is an organic bromide salt having (1alpha,2beta,4beta,5alpha,7beta)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0(2,4)]nonane as the counterion. Used (in the form of the hydrate) for maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease. It has a role as a bronchodilator agent and a muscarinic antagonist. It is an organic bromide salt and a quaternary ammonium salt. |
| Classification | Unknown |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21.[Br-] |
Identifiers
| PDB | — |
| CAS-ID | 136310-93-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4440620 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | XX112XZP0J (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,927 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
84,652 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more